UNSPSC 51342710: Interferon beta-1b

This classification denotes an interferon, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TTD90R31WZ. European Medicines Agency schedules Interferon alfa-n1 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12432MIG. As of Q4 2014, INTERFERON BETA-1B remains the US FDA Preferred Term for this commodity. Interferon beta-1b bears US NLM identifiers UMLS ID C0244714 and NCI Concept Code C2221. SMILES: NONE.

UNSPSC 51342710 Interferon beta-1b is a Commodity code that nominally designates a single pharmaceutical product, but recent state and local procurement activity under this code shows minimal direct relevance to the interferon beta-1b specification itself. Instead, the opportunities posted against this code span a wider range of pharmaceutical procurement activities, including emergency response medications, over-the-counter products, and pharmacy benefit management programs. The issuing bodies soliciting under the code include county health departments, state health and human services agencies, municipal fire departments, and multistate cooperative purchasing alliances. The work actually being bought reflects state and local demand for managed pharmaceutical sourcing, emergency medical supplies, and direct-to-manufacturer contracting models to support public health, emergency response, and employee benefit programs.

Activity appears concentrated in Florida and Minnesota, with exploratory procurement in Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure naloxone and drug deactivation systems for community health initiatives, with quarterly deliveries to the county health building and a July 26, 2023 response deadline. The City of Tampa issued a sheltered-market ITB (26P00145) in March 2026 for medical and first aid supplies—including respiratory equipment, cardiac monitoring electrodes, and consumables—for the Tampa Fire Department Rescue Division, designated exclusively for certified Small Local Business Enterprises with an estimated contract value of $700,000 and a March 13, 2026 due date. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), posted an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. The Texas Health and Human Services Commission issued an RFI in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program targeting self-insured state and local plans, signaling early-stage procurement development rather than immediate buying.